TY - JOUR AU - Stock, W. AU - Johnson, J. L. AU - Stone, R. M. AU - Kolitz, J. E. AU - Powell, B. L. AU - Wetzler, M. PY - 2013 DA - 2013// TI - Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802 JO - Cancer VL - 119 UR - https://doi.org/10.1002/cncr.27617 DO - 10.1002/cncr.27617 ID - Stock2013 ER - TY - JOUR AU - Thomas, D. A. AU - O'Brien, S. AU - Faderl, S. AU - Garcia-Manero, G. AU - Ferrajoli, A. AU - Wierda, W. PY - 2010 DA - 2010// TI - Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.9456 DO - 10.1200/JCO.2009.26.9456 ID - Thomas2010 ER - TY - JOUR AU - Jabbour, E. AU - O'Brien, S. AU - Ravandi, F. AU - Kantarjian, H. PY - 2015 DA - 2015// TI - Monoclonal antibodies in acute lymphoblastic leukemia JO - Blood VL - 125 UR - https://doi.org/10.1182/blood-2014-08-596403 DO - 10.1182/blood-2014-08-596403 ID - Jabbour2015 ER - TY - JOUR AU - O'Brien, S. AU - Schiller, G. AU - Lister, J. AU - Damon, L. AU - Goldberg, S. AU - Aulitzky, W. PY - 2013 DA - 2013// TI - High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.46.2309 DO - 10.1200/JCO.2012.46.2309 ID - O'Brien2013 ER - TY - JOUR AU - Kantarjian, H. AU - Gandhi, V. AU - Cortes, J. AU - Verstovsek, S. AU - Du, M. AU - Garcia-Manero, G. PY - 2003 DA - 2003// TI - Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia JO - Blood VL - 102 UR - https://doi.org/10.1182/blood-2003-03-0925 DO - 10.1182/blood-2003-03-0925 ID - Kantarjian2003 ER - TY - JOUR AU - Maury, S. AU - Huguet, F. AU - Leguay, T. AU - Lacombe, F. AU - Maynadie, M. AU - Girard, S. PY - 2010 DA - 2010// TI - Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia JO - Haematologica VL - 95 UR - https://doi.org/10.3324/haematol.2009.010306 DO - 10.3324/haematol.2009.010306 ID - Maury2010 ER - TY - JOUR AU - Hoelzer, D. AU - Walewski, J. AU - Dohner, H. AU - Viardot, A. AU - Hiddemann, W. AU - Spiekermann, K. PY - 2014 DA - 2014// TI - Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-03-563627 DO - 10.1182/blood-2014-03-563627 ID - Hoelzer2014 ER - TY - STD TI - Thomas DA, KH JJ, Faderl S, Jabbour E, Konopleva M, et al. Outcomes continue to be favorable for de novo Philadelphia chromosome negative B-lymphoblastic leukemia (ALL) after therapy with hyper-CVAD (with or without rituximab) regimen. Blood. 2012;120(suppl): abstract 3572. ID - ref8 ER - TY - STD TI - Sébastien Maury SC, Xavier T, Dominik H, Thibaut L, Françoise H, Patrice C, et al. Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): results of the randomized Graall-R 2005 study. Blood. 2015;126(suppl): abstract 1. ID - ref9 ER - TY - JOUR AU - Maury, S. AU - Chevret, S. AU - Thomas, X. AU - Heim, D. AU - Leguay, T. AU - Huguet, F. PY - 2016 DA - 2016// TI - Rituximab in B-lineage adult acute lymphoblastic leukemia JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1605085 DO - 10.1056/NEJMoa1605085 ID - Maury2016 ER - TY - JOUR AU - Rai, K. R. PY - 2015 DA - 2015// TI - Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0165-x DO - 10.1186/s13045-015-0165-x ID - Rai2015 ER - TY - JOUR AU - Awasthi, A. AU - Ayello, J. AU - Ven, C. AU - Elmacken, M. AU - Sabulski, A. AU - Barth, M. J. PY - 2015 DA - 2015// TI - Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL JO - Br J Haematol VL - 171 UR - https://doi.org/10.1111/bjh.13764 DO - 10.1111/bjh.13764 ID - Awasthi2015 ER - TY - STD TI - Koji SP, Hagop MK, Deborah AT, Maria RK, Guillermo GM, Rebecca G, et al. Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood 2015;126(suppl): abstract 1295. ID - ref13 ER - TY - STD TI - Koji SH, Farhad R, Naval D, Tapan MK, Rita BK, Yesid A, et al. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood. 2016;128(suppl): abstract 2783. ID - ref14 ER - TY - JOUR AU - Tobinai, K. AU - Klein, C. AU - Oya, N. AU - Fingerle-Rowson, G. PY - 2017 DA - 2017// TI - A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies JO - Adv Ther VL - 34 UR - https://doi.org/10.1007/s12325-016-0451-1 DO - 10.1007/s12325-016-0451-1 ID - Tobinai2017 ER - TY - JOUR AU - Blanc, V. AU - Bousseau, A. AU - Caron, A. AU - Carrez, C. AU - Lutz, R. J. AU - Lambert, J. M. PY - 2011 DA - 2011// TI - SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-11-0485 DO - 10.1158/1078-0432.CCR-11-0485 ID - Blanc2011 ER - TY - JOUR AU - Younes, A. AU - Kim, S. AU - Romaguera, J. AU - Copeland, A. AU - Farial Sde, C. AU - Kwak, L. W. PY - 2012 DA - 2012// TI - Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.4403 DO - 10.1200/JCO.2011.39.4403 ID - Younes2012 ER - TY - JOUR AU - Carol, H. AU - Szymanska, B. AU - Evans, K. AU - Boehm, I. AU - Houghton, P. J. AU - Smith, M. A. PY - 2013 DA - 2013// TI - The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-3613 DO - 10.1158/1078-0432.CCR-12-3613 ID - Carol2013 ER - TY - JOUR AU - Kantarjian, H. M. AU - Lioure, B. AU - Kim, S. K. AU - Atallah, E. AU - Leguay, T. AU - Kelly, K. PY - 2016 DA - 2016// TI - A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia JO - Clin Lymphoma Myeloma Leuk VL - 16 UR - https://doi.org/10.1016/j.clml.2015.12.004 DO - 10.1016/j.clml.2015.12.004 ID - Kantarjian2016 ER - TY - STD TI - Amir TF, Tanya MT, Maureen MO, Daniel JD, Bijal DS, Todd MC, et al. Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma. Blood. 2014;124(suppl): abstract 963. ID - ref20 ER - TY - JOUR AU - Wu, J. AU - Fu, J. AU - Zhang, M. AU - Liu, D. PY - 2015 DA - 2015// TI - Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0195-4 DO - 10.1186/s13045-015-0195-4 ID - Wu2015 ER - TY - JOUR AU - Fan, G. AU - Wang, Z. AU - Hao, M. AU - Li, J. PY - 2015 DA - 2015// TI - Bispecific antibodies and their applications JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0227-0 DO - 10.1186/s13045-015-0227-0 ID - Fan2015 ER - TY - JOUR AU - Klinger, M. AU - Brandl, C. AU - Zugmaier, G. AU - Hijazi, Y. AU - Bargou, R. C. AU - Topp, M. S. PY - 2012 DA - 2012// TI - Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2012-01-400515 DO - 10.1182/blood-2012-01-400515 ID - Klinger2012 ER - TY - JOUR AU - Topp, M. S. AU - Kufer, P. AU - Gokbuget, N. AU - Goebeler, M. AU - Klinger, M. AU - Neumann, S. PY - 2011 DA - 2011// TI - Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.32.7270 DO - 10.1200/JCO.2010.32.7270 ID - Topp2011 ER - TY - JOUR AU - Jeune, C. AU - Thomas, X. PY - 2016 DA - 2016// TI - Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia JO - Drug Des Devel Ther VL - 10 ID - Jeune2016 ER - TY - STD TI - Nicola GH, Massimiliano B, Albrecht R, Carlos G, Christoph F, Helmut D, et al. Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL). Blood. 2015;126(suppl): abstract 680. ID - ref26 ER - TY - JOUR AU - Topp, M. S. AU - Gokbuget, N. AU - Zugmaier, G. AU - Klappers, P. AU - Stelljes, M. AU - Neumann, S. PY - 2014 DA - 2014// TI - Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2014.56.3247 DO - 10.1200/JCO.2014.56.3247 ID - Topp2014 ER - TY - JOUR AU - Topp, M. S. AU - Gokbuget, N. AU - Stein, A. S. AU - Zugmaier, G. AU - O'Brien, S. AU - Bargou, R. C. PY - 2015 DA - 2015// TI - Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71170-2 DO - 10.1016/S1470-2045(14)71170-2 ID - Topp2015 ER - TY - JOUR AU - Francis, J. AU - Dharmadhikari, A. V. AU - Sait, S. N. AU - Deeb, G. AU - Wallace, P. K. AU - Thompson, J. E. PY - 2013 DA - 2013// TI - CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations JO - Leuk Lymphoma VL - 54 UR - https://doi.org/10.3109/10428194.2012.754096 DO - 10.3109/10428194.2012.754096 ID - Francis2013 ER - TY - STD TI - Duell J, Dittrich M, Bedke T, Mueller T, Rasche L, Dandekar T, et al. Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients. Blood. 2014;124(suppl): abstract 2291. ID - ref30 ER - TY - JOUR AU - Kohnke, T. AU - Krupka, C. AU - Tischer, J. AU - Knosel, T. AU - Subklewe, M. PY - 2015 DA - 2015// TI - Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0213-6 DO - 10.1186/s13045-015-0213-6 ID - Kohnke2015 ER - TY - JOUR AU - Ma, W. AU - Gilligan, B. M. AU - Yuan, J. AU - Li, T. PY - 2016 DA - 2016// TI - Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0277-y DO - 10.1186/s13045-016-0277-y ID - Ma2016 ER - TY - JOUR AU - Fan, D. AU - Li, W. AU - Yang, Y. AU - Zhang, X. AU - Zhang, Q. AU - Yan, Y. PY - 2015 DA - 2015// TI - Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0205-6 DO - 10.1186/s13045-015-0205-6 ID - Fan2015 ER - TY - STD TI - Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003;9(suppl):3982s–3990s. ID - ref34 ER - TY - JOUR AU - Lumb, S. AU - Fleischer, S. J. AU - Wiedemann, A. AU - Daridon, C. AU - Maloney, A. AU - Shock, A. PY - 2016 DA - 2016// TI - Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor JO - J Cell Commun Signal VL - 10 UR - https://doi.org/10.1007/s12079-016-0322-1 DO - 10.1007/s12079-016-0322-1 ID - Lumb2016 ER - TY - STD TI - Raetz EA CM, Borowitz MJ. Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from Children’s Oncology Group (COG) study. Blood. 2011;118(suppl): abstract 573. ID - ref36 ER - TY - JOUR AU - Advani, A. S. AU - McDonough, S. AU - Coutre, S. AU - Wood, B. AU - Radich, J. AU - Mims, M. PY - 2014 DA - 2014// TI - SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia JO - Br J Haematol VL - 165 UR - https://doi.org/10.1111/bjh.12778 DO - 10.1111/bjh.12778 ID - Advani2014 ER - TY - STD TI - Patrice SC, Françoise H, Emmanuel R, Xavier T, Thibaut L, Tony M, et al. Hyper-CVAD plus epratuzumab as salvage regimen for younger relapsed/refractory CD22+ B acute lymphoblastic leukemia (ALL) patients: results of the Phase 2 Prospective Cheprall Study. Blood. 2016;128(suppl): abstract 4018. ID - ref38 ER - TY - JOUR AU - Jabbour, E. J. AU - Kantarjian, H. AU - Eliasson, L. AU - Cornelison, A. M. AU - Marin, D. PY - 2012 DA - 2012// TI - Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia JO - Am J Hematol VL - 87 UR - https://doi.org/10.1002/ajh.23180 DO - 10.1002/ajh.23180 ID - Jabbour2012 ER - TY - JOUR AU - Kantarjian, H. AU - Thomas, D. AU - Jorgensen, J. AU - Kebriaei, P. AU - Jabbour, E. AU - Rytting, M. PY - 2013 DA - 2013// TI - Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia JO - Cancer VL - 119 UR - https://doi.org/10.1002/cncr.28136 DO - 10.1002/cncr.28136 ID - Kantarjian2013 ER - TY - JOUR AU - Kantarjian, H. M. AU - DeAngelo, D. J. AU - Stelljes, M. AU - Martinelli, G. AU - Liedtke, M. AU - Stock, W. PY - 2016 DA - 2016// TI - Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1509277 DO - 10.1056/NEJMoa1509277 ID - Kantarjian2016 ER - TY - STD TI - Koji SE, Susan MO, Farhad R, Deborah AT, Tapan MK, Guillermo GM, et al. Phase II study of the salvage mini-hyper-CVD in combination with inotuzumab ozogamicin (INO) for adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Blood. 2016;128(suppl): abstract 1606. ID - ref42 ER - TY - STD TI - Koji SE, Susan MO, Farhad R, Deborah AT, Tapan MK, Guillermo GM, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia (ALL): interim result of a phase II clinical trial. blood;128(suppl): abstract 588. ID - ref43 ER - TY - STD TI - Wendy SB, Gerard L, Ravi V, John CB, Bayard LP, Meir W, et al. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a cancer and leukemia group B study (CALGB 10102). Blood. 2009;114(suppl): abstract 838. ID - ref44 ER - TY - JOUR AU - Gorin, N. C. AU - Isnard, F. AU - Garderet, L. AU - Ikhlef, S. AU - Corm, S. AU - Quesnel, B. PY - 2013 DA - 2013// TI - Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study JO - Eur J Haematol VL - 91 ID - Gorin2013 ER - TY - JOUR AU - Barrett, D. M. AU - Singh, N. AU - Porter, D. L. AU - Grupp, S. A. AU - June, C. H. PY - 2014 DA - 2014// TI - Chimeric antigen receptor therapy for cancer JO - Annu Rev Med VL - 65 UR - https://doi.org/10.1146/annurev-med-060512-150254 DO - 10.1146/annurev-med-060512-150254 ID - Barrett2014 ER - TY - JOUR AU - Maus, M. V. AU - Grupp, S. A. AU - Porter, D. L. AU - June, C. H. PY - 2014 DA - 2014// TI - Antibody-modified T cells: CARs take the front seat for hematologic malignancies JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2013-11-492231 DO - 10.1182/blood-2013-11-492231 ID - Maus2014 ER - TY - JOUR AU - Brentjens, R. J. AU - Santos, E. AU - Nikhamin, Y. AU - Yeh, R. AU - Matsushita, M. AU - Perle, K. PY - 2007 DA - 2007// TI - Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-0674 DO - 10.1158/1078-0432.CCR-07-0674 ID - Brentjens2007 ER - TY - JOUR AU - Davila, M. L. AU - Kloss, C. C. AU - Gunset, G. AU - Sadelain, M. PY - 2013 DA - 2013// TI - CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0061338 DO - 10.1371/journal.pone.0061338 ID - Davila2013 ER - TY - JOUR AU - Hu, Y. AU - Sun, J. AU - Wu, Z. AU - Yu, J. AU - Cui, Q. AU - Pu, C. PY - 2016 DA - 2016// TI - Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0299-5 DO - 10.1186/s13045-016-0299-5 ID - Hu2016 ER - TY - JOUR AU - Maude, S. L. AU - Frey, N. AU - Shaw, P. A. AU - Aplenc, R. AU - Barrett, D. M. AU - Bunin, N. J. PY - 2014 DA - 2014// TI - Chimeric antigen receptor T cells for sustained remissions in leukemia JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1407222 DO - 10.1056/NEJMoa1407222 ID - Maude2014 ER - TY - JOUR AU - Lee, D. W. AU - Kochenderfer, J. N. AU - Stetler-Stevenson, M. AU - Cui, Y. K. AU - Delbrook, C. AU - Feldman, S. A. PY - 2015 DA - 2015// TI - T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial JO - Lancet VL - 385 UR - https://doi.org/10.1016/S0140-6736(14)61403-3 DO - 10.1016/S0140-6736(14)61403-3 ID - Lee2015 ER - TY - STD TI - Jae H, Park IR, Wang X, Yvette B, Terence P, Halton E, et al. Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL. Blood. 2015;126(suppl): abstract 682. ID - ref53 ER - TY - STD TI - Lee DW, Yuan CM, Shah NN, Delbrook C, Yates B, Zhang H, et al. Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation. Blood. 2016;128(suppl): abstract 218. ID - ref54 ER - TY - STD TI - Shah B, Sender LS, Lee DW, Castro JE, Wierda WG, Dietz AC, et al. High rates of minimal residual disease-negative (MRD−) complete responses (CR) in adult and pediatric and patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cells): preliminary results of the ZUMA-3 and ZUMA-4 trials. Blood. 2016;128(suppl): abstract 2803. ID - ref55 ER - TY - STD TI - Grupp SA, Shaw PA, Aplenc R, Barrett DM, Callahan C, Lacey SF, et al. Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood. 2015;126(suppl): abstract 681. ID - ref56 ER - TY - STD TI - Grupp SA, Buechner J, Bittencourt H, Maude SL, Verneris MR, Myers GD, et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood. 2016;128(suppl): abstract 221. ID - ref57 ER - TY - STD TI - Maude SL, Boyer MW, Grupp SA, Davies SM, Phillips CL, Verneris MR, et al. Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood. 2016;128(suppl): abstract 2801. ID - ref58 ER - TY - JOUR AU - Liu, J. AU - Zhong, J. F. AU - Zhang, X. AU - Zhang, C. PY - 2017 DA - 2017// TI - Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0405-3 DO - 10.1186/s13045-017-0405-3 ID - Liu2017 ER - TY - JOUR AU - Kochenderfer, J. N. AU - Dudley, M. E. AU - Carpenter, R. O. AU - Kassim, S. H. AU - Rose, J. J. AU - Telford, W. G. PY - 2013 DA - 2013// TI - Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-08-519413 DO - 10.1182/blood-2013-08-519413 ID - Kochenderfer2013 ER - TY - JOUR AU - Cruz, C. R. AU - Micklethwaite, K. P. AU - Savoldo, B. AU - Ramos, C. A. AU - Lam, S. AU - Ku, S. PY - 2013 DA - 2013// TI - Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-06-506741 DO - 10.1182/blood-2013-06-506741 ID - Cruz2013 ER - TY - JOUR AU - Brudno, J. N. AU - Somerville, R. P. AU - Shi, V. AU - Rose, J. J. AU - Halverson, D. C. AU - Fowler, D. H. PY - 2016 DA - 2016// TI - Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.5929 DO - 10.1200/JCO.2015.64.5929 ID - Brudno2016 ER - TY - STD TI - Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016;108: djv439. doi: 10.1093/jnci/djv439 ID - ref63 ER - TY - STD TI - Smith M, James S, Davila ML, Velardi E, Argyropoulos EV, Gunset G, et al. Murine donor 1928z CAR T cells exert potent graft-versus-lymphoma activity without graft-versus-host-disease. Blood. 2016;128 (suppl): abstract 653. ID - ref64 ER - TY - STD TI - Cai B, Guo M, Wang Y, Zhang Y, Yang J, Guo Y, et al. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. J Hematol Oncol. 2016;9(1):131. ID - ref65 ER - TY - STD TI - Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95. ID - ref66 ER - TY - JOUR AU - Barrett, D. M. AU - Teachey, D. T. AU - Grupp, S. A. PY - 2014 DA - 2014// TI - Toxicity management for patients receiving novel T-cell engaging therapies JO - Curr Opin Pediatr VL - 26 UR - https://doi.org/10.1097/MOP.0000000000000043 DO - 10.1097/MOP.0000000000000043 ID - Barrett2014 ER - TY - JOUR AU - Grupp, S. A. AU - Kalos, M. AU - Barrett, D. AU - Aplenc, R. AU - Porter, D. L. AU - Rheingold, S. R. PY - 2013 DA - 2013// TI - Chimeric antigen receptor-modified T cells for acute lymphoid leukemia JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1215134 DO - 10.1056/NEJMoa1215134 ID - Grupp2013 ER - TY - JOUR AU - Dummy PY - 2016 DA - 2016// TI - From CARs to TRUCKs and beyond: safely en route to adoptive T-cell therapy for cancer JO - EBio Medicine VL - 14 ID - Dummy2016 ER - TY - JOUR AU - Maude, S. L. AU - Teachey, D. T. AU - Porter, D. L. AU - Grupp, S. A. PY - 2015 DA - 2015// TI - CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia JO - Blood VL - 125 UR - https://doi.org/10.1182/blood-2014-12-580068 DO - 10.1182/blood-2014-12-580068 ID - Maude2015 ER - TY - STD TI - Gardner R, Smithers H, Leger KJ, Annesley CE, Summers C, Brown C, et al. CD19CAR T cell products of defined CD4:CD8 composition and transgene expression show prolonged persistence and durable MRD-negative remission in pediatric and young adult B-cell ALL. Blood. 2016;128(suppl): abstract 219. ID - ref71 ER - TY - JOUR AU - Turtle, C. J. AU - Hanafi, L. A. AU - Berger, C. AU - Gooley, T. A. AU - Cherian, S. AU - Hudecek, M. PY - 2016 DA - 2016// TI - CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients JO - J Clin Invest VL - 126 UR - https://doi.org/10.1172/JCI85309 DO - 10.1172/JCI85309 ID - Turtle2016 ER - TY - STD TI - Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C, et al. Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood. 2015;126(suppl): abstract 681. ID - ref73 ER - TY - STD TI - Maude SL, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Baniewicz D, et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed/refractory acute lymphoblastic leukemia. Blood. 2016;128 (suppl): abstract 217. ID - ref74 ER - TY - JOUR AU - Corrigan-Curay, J. AU - Kiem, H. P. AU - Baltimore, D. AU - O'Reilly, M. AU - Brentjens, R. J. AU - Cooper, L. PY - 2014 DA - 2014// TI - T-cell immunotherapy: looking forward JO - Mol Ther VL - 22 UR - https://doi.org/10.1038/mt.2014.148 DO - 10.1038/mt.2014.148 ID - Corrigan-Curay2014 ER - TY - STD TI - Maude SL, Hucks GE, Seif AE, Talekar MK, Teachey DT, Baniewicz D, et al. The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). J Clin Oncol. 2017;35(suppl): abstract 103. ID - ref76 ER - TY - STD TI - Gill S, Frey NV, Hexner EO, Lacey SF, Melenhorst JJ, Byrd JC, et al. CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. J Clin Oncol. 2017;35(suppl): abstract 7509. ID - ref77 ER - TY - STD TI - Lacey SF, Xu J, Ruella M. Cars in leukemia: relapse with antigen-negative leukemia originating from a single B cell expressing the leukemia-targeting CAR. Blood 2016, 128 (suppl): abstract 281; ID - ref78 ER - TY - JOUR AU - Long, A. H. AU - Haso, W. M. AU - Orentas, R. J. PY - 2013 DA - 2013// TI - Lessons learned from a highly-active CD22-specific chimeric antigen receptor JO - Oncoimmunology VL - 2 UR - https://doi.org/10.4161/onci.23621 DO - 10.4161/onci.23621 ID - Long2013 ER - TY - JOUR AU - Haso, W. AU - Lee, D. W. AU - Shah, N. N. AU - Stetler-Stevenson, M. AU - Yuan, C. M. AU - Pastan, I. H. PY - 2013 DA - 2013// TI - Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2012-06-438002 DO - 10.1182/blood-2012-06-438002 ID - Haso2013 ER - TY - STD TI - Shah nn, Yuan CM, Shalabi H, Yates B, Delbrook C, Zhang L, et al. Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood. 2016;128(suppl): abstract 650. ID - ref81 ER -